Medicine composite for treating vaginitis

A composition and vaginitis technology, applied in the field of pharmaceutical preparations, can solve the problems of affecting the curative effect, easy leakage, low curative effect, etc., and achieve the effects of improving drug compliance, prolonging contact time, and prolonging release time

Active Publication Date: 2010-04-28
SHENZHEN SOUTH CHINA PHARMA
View PDF0 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] 1) easy to leak
After the common preparation is used, it is easy to leak out under the action of vaginal secretions and excretions. On the one hand, the drug will be lost and the curative effect cannot be guaranteed. Finally, the lying position is adopted, which brings great inconvenience to the patient and reduces the patient's compliance with medication.
[0008] 2) frequent use of medication
Due to the problems of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composite for treating vaginitis
  • Medicine composite for treating vaginitis

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0072] Example 1.

[0073] Composition of prescription:

[0074] Butoconazole nitrate 2%

[0075] Poloxamer F127 17%

[0076] Carbomer 934 0.5%

[0077] Hypromellose K4M 1.5%

[0078] Methyl Paraben 0.15%

[0079] Water balance

[0080] Preparation:

[0081] Take methyl paraben, add water to dissolve and stir evenly, while stirring, add poloxamer, carbomer, hypromellose, and place it at 4°C. After it is fully dissolved, add the 200 mesh sieve Stir the butoconazole nitrate evenly, distribute it into the vaginal applicator, and get 5g each.

Example Embodiment

[0082] Example 2.

[0083] Composition of prescription:

[0084] Butoconazole nitrate 100mg

[0085] Hypromellose K4M 400mg

[0086] Carbomer 947 100mg

[0087] Polyethylene glycol 4000 200mg

[0088] Preparation:

[0089] 1. Take butoconazole nitrate through a 200-mesh sieve, hypromellose, polyethylene glycol and carbomer respectively through an 80-mesh sieve, mix well, add 80% ethanol solution to make a suitable softener, and go through an 18-mesh sieve Prepare granules and dry them at 40~50℃ to obtain dry granules;

[0090] 2. The dry granules are sieved through a 20-mesh sieve, and talc powder (added at 1% of the total granules) is added as a glidant and lubricant, mixed well, and the granule content is determined;

[0091] 3. Compress tablets, each containing 100mg of butoconazole nitrate, and pack it immediately.

Example Embodiment

[0092] Example 3.

[0093] Composition of prescription:

[0094] Butoconazole nitrate 1%

[0095] Hydroxypropyl beta cyclodextrin 40%

[0096] Poloxamer F127 17%

[0097] Hypromellose K4M 2%

[0098] Methyl paraben 0.5%

[0099] Propylparaben 0.5%

[0100] Disodium edetate 0.01%

[0101] Water margin.

[0102] Preparation:

[0103] Take butoconazole nitrate and hydroxypropyl beta cyclodextrin, add water and continue stirring to dissolve, add disodium edetate, methyl paraben and propyl paraben, stir to dissolve, add poloxat while stirring Hypromellose and hypromellose are placed at 4°C. After they are fully dispersed, they are divided into a vaginal applicator, 10g each, ready to be obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine composite for treating vaginitis, comprising main medicine, matrix, bio-adhesive material, release rate regulator and other additives. The medicine composite for treating vaginitis has special bioadhesive and longer keeping time, reduces medicine leakage, prolongs contact time of medicine and vagina mucosa and ensures curative effect; the composite has special vagina slow release performance and can continuously release medicine for 2-7 days; compared with common preparation, the medicine composite prolongs medicine release time and can reduce medicine application times, thus bringing convenience for patients to apply the medicine. Meanwhile, because the medicine composite has the characteristics of bioadhesive and long efficiency of slow release and has no requirements for medicine application time, thus medicine application can be carried out at any time.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition for treating vaginitis. Background technique [0002] Gynecological inflammation is a common disease in women. About 87% of adult women in the world have been infected with gynecological inflammation to varying degrees. Common clinical gynecological inflammations include vaginitis, cervicitis, pelvic inflammatory disease, endometritis, etc. Among them, the incidence of vaginitis The highest, accounting for about one-third of gynecological inflammation. Vaginitis is mainly divided into fungal vaginitis, bacterial vaginitis, and trichomonas vaginitis. Bacterial vaginosis and fungal vaginitis have the highest incidence rates. These two kinds of vaginitis have different incidence rates in different countries and regions. In the United States, the incidence rate of bacterial vaginosis is high, while in Europe, the incidence rate of fun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/4174A61K31/496A61K31/4164A61K47/32A61K47/34A61K47/36A61K47/38A61K47/40A61K47/44A61P15/02A61K47/10
Inventor 巩洪刚邓文军常建晖郑国玲邓树海
Owner SHENZHEN SOUTH CHINA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap